SEC Form 4 · accession 0001179110-15-010309
KYTHERA BIOPHARMACEUTICALS INC · KYTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
III Frederick Beddingfield
Officer — Chief Medical Officer
Period of report
Jun 24, 2015
Accepted (ET)
Jun 25, 2015 · 6:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001436304
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 24, 2015 | S | 11,040 | $75.5235 | D | 19,543 | D | |
| Common StockF1 | Jun 25, 2015 | S | 19,543 | $75.7425 | D | 0 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $75.50 to $75.75, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.